| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7467a48b737f14264afc0ca2207cea2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4705 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2002-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3849d71737cc61ac9d90e1caf41df884 |
| publicationDate |
2004-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004241797-A1 |
| titleOfInvention |
Use of alphacp1, alphacp2, and hur for modulating gene expression and inducing angiogenesis |
| abstract |
The present invention describes methods for modulating gene expression, stabilizing VEGF mRNAs, for inducing angiogenesis, for treating various mammalian diseases including coronary and cardiac diseases and for identifying modulators of gene expression by using human proteins called αCP1, αCP2 and HuR. The invention also describes mRNA stabilizing elements and consensus sequences involved in binding of αCP1, αCP2 and HuR proteins to mRNAs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019153008-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010107960-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005042643-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011041582-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011041584-A2 |
| priorityDate |
2001-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |